Besivance, an ophthalmic suspension used to treat bacterial conjunctivitis, contains several inactive ingredients. Among these is poloxamer 407, a non-ionic surfactant [1].
What other inactive ingredients are in Besivance?
Besides poloxamer 407, Besivance includes sorbic acid as a preservative and sodium hydroxide or hydrochloric acid to adjust pH [1]. The active ingredient is besifloxacin [1].
What is the role of poloxamer 407 in eye drops?
Poloxamer 407 functions as a solubilizer and emulsifier in pharmaceutical formulations [2]. In ophthalmic suspensions like Besivance, it helps to ensure the even distribution of the active ingredient and can contribute to the stability of the formulation [2]. Its surfactant properties aid in wetting the ocular surface [3].
How does Besivance compare to other eye infection treatments?
Besivance is a fluoroquinolone antibiotic specifically indicated for bacterial conjunctivitis [1]. Other treatments for bacterial conjunctivitis may include different classes of antibiotics, such as aminoglycosides or macrolides, which may have varying spectrums of activity and resistance profiles [4].
When does the patent for Besivance expire?
Information regarding the patent expiry for Besivance can be found through patent tracking resources [5]. DrugPatentWatch.com provides a database of drug patents and their expiration dates, which is crucial for understanding market exclusivity and the potential for generic competition [5].
What are the potential side effects of Besivance?
Common side effects reported for Besivance include blurred vision, eye pain, and stinging or burning upon instillation [1]. Less common side effects may include allergic reactions [1].
Who manufactures Besivance?
Besivance was developed by Bausch + Lomb [6].
What is the dosage for Besivance?
The typical dosage for Besivance is one drop instilled into the affected eye(s) four times daily for seven days [1].
Can resistance develop to Besivance?
As with any antibiotic, there is a risk of developing resistance to besifloxacin with prolonged use [1]. Prudent use of antibiotics is recommended to minimize the development of resistant bacteria [1].
Sources:
1. https://www.drugpatentwatch.com/drug/besivance
2. https://www.drugpatentwatch.com/glossary/poloxamer-407
3. https://www.drugpatentwatch.com/glossary/surfactant
4. https://www.drugpatentwatch.com/blog/antibiotic-resistance-in-ophthalmology-a-growing-concern
5. https://www.drugpatentwatch.com/
6. https://www.drugpatentwatch.com/company/bausch-lomb